### **Biomarkers and Omics**



# High selectivity quantification of protein isoforms using MRM<sup>3</sup> Workflow

CYP450 isoform quantification Using the QTRAP® 4500 System

## Kelli Jonakin, Christie Hunter SCIEX, USA

The cytochrome P450 protein superfamily of mono-oxygenases is the major phase-I enzyme system responsible for metabolism of most drugs and other foreign chemicals, frequently resulting in the formation of toxic drug metabolites. In higher eukaryotes, there are over 70 families of P450s involved in drug metabolism, comprising over 200 different isoforms, with diverse substrate specificities and inducible by different drugs or chemicals. These proteins share substantial sequence homology making quantification of specific isoforms challenging.

Quantitation of proteins by Multiple Reaction Monitoring (MRM) requires selection of peptides which are unique to the sequence of the protein of interest. When a protein is part of a protein family with very high sequence similarity, this can often restrict the choice of unique peptides for quantification to those that are not proteotypic, and are present at lower abundance. Therefore, having an additional level of selectivity in the MS quantification methods can be of upmost importance for the analysis of similar protein isoforms in complex matrices. The MRM<sup>3</sup> workflow<sup>1</sup> that is possible on the QTRAP 5500 and 4500 Systems is a high selectivity method that provides additional specificity by monitoring the secondary product ions of a peptide of interest, rather than just the product ions (Figure 1). In this work, the CYP450 3A5 protein (which shares ~80% amino acid sequence identity with isoform 3A4) is specifically quantified in liver microsomes by monitoring unique peptides to 3A5 protein.



## Key features of the QTRAP 4500 System for peptide quantification

High sensitivity, fast scanning linear ion trap enables the MRM<sup>3</sup> workflow for high selectivity quantification of peptides in complex proteomic matrices (Figure 1).

- High ion trap sensitivity the QTRAP 4500 System features a high sensitivity ion trap mass analyzer
- Faster linear ion trap scan speeds Scan speeds up to 20,000 Da/sec enable MS<sup>3</sup> scans with an HPLC compatible cycle time. Extracted ion chromatograms (XICs) of second generation product ions can be extracted and integrated with a sufficient number of data points across the chromatographic peak.

• Better in-trap fragmentation – the Linear Accelerator™ Trap with pulsed gas valve implemented in the QTRAP 4500 System provides faster, more efficient in-trap fragmentation

• High selectivity – Unit isolation of precursor ions in Q1 followed by excitation and fragmentation at unit resolution in the ion trap provides the highest available selectivity in MRM<sup>3</sup> analysis







#### **Methods**

**Sample preparation:** Synthetic tryptic peptides to the CYP450 3A5 protein (both isotopically heavy and light) were used to design MRM and MRM<sup>3</sup> assays (Figure 2). Standard concentration curves were constructed using the standard peptides in digested human liver microsomes (~1 ug of protein matrix on column). Light peptides were added as an internal standard and heavy labeled peptides dosed at levels between 305 amol to 805 fmol on column.

**Chromatography:** Analysis of peptide quantitation curves was performed on a nanoflow LC system in trap elute mode. In each injection, sample was desalted on a 200  $\mu$ m x 6 mm trap and then eluted onto a 200  $\mu$ m x 150 mm column for MS analysis. Both the trap and column chips were filled with ChromXP<sup>TM</sup> C18-CL 3 $\mu$ m 120Å reversed phase material. Peptides were separated using a linear gradient formed by A (2% ACN, 0.1% FA) and B (98% ACN, 0.1% FA) from 10–30% of B over 45 minutes at a flow of 1  $\mu$ L/min.

*Mass spectrometry:* The MS analysis was performed on a QTRAP 4500 System (SCIEX) using MRM and MRM<sup>3</sup> analysis. MRM analysis was performed at Unit resolution in both Q1 and Q3 quadrupoles. MRM<sup>3</sup> analysis was performed using the MS/MS/MS scan function. Precursor ions were isolated in Q1 using unit resolution, first-generation product ions were generated in the Q2 collision cell using an optimized collision energy and trapped in the Q3 linear ion trap for 100 ms. A suitable first-generation product ion was isolated and further excited by resonance excitation for 25 ms to produce second-generation fragments, which are scanned out of the trap at 10000 Da/sec for a total cycle time of 1370 ms per peptide.



**Figure 3. Comparing MRM and MRM<sup>3</sup> specificity.** MRM<sup>3</sup> workflow provides high specificity by quantifying secondary product ions generated from a peptide of interest. Two of three MRM transitions detected for the DTINFLSK peptide of CYP450 3a5 (top) show significant interferences at 4.9 fmol on column, where MRM<sup>3</sup> detection of secondary product ions from the peptide (bottom) provide a more selective detection.



**Figure 2. MRM<sup>3</sup> assay design.** A dominant product ion from the MS/MS spectrum (top) is selected for MS/MS/MS analysis (middle). Multiple product ions can be assessed to find which produces the best secondary product ion spectrum. Analysis of the MS<sup>3</sup> fragmentation is used to optimize the excitation energy and select the best second-generation fragments to extract and use in quantitation. Multiple second-generation fragments can be used to generate MRM<sup>3</sup> XICs (bottom). Data shown here is for the CYP450 peptide DTINFLSK, at 4.9 fmol on column.

*Data processing:* Data was processed using MultiQuant<sup>™</sup> Software. MRM peak areas were integrated, either individually or summed together. MRM<sup>3</sup> peak areas were determined by summing the integration of secondary product ions using extraction widths of 0.5 Da.



#### Developing MRM and MRM<sup>3</sup> assays

When a peptide is fragmented in the collision cell, a number of product ions are generated that can be assessed for use in MRM<sup>3</sup> experiment (Figure 2, top). For the DTINFLSK peptide, the dominant y5 ion was isolated and fragmented in the linear ion trap to generate an MS<sup>3</sup> spectrum (Figure 2, middle). Multiple secondary product ions are extracted using a width of 0.5 Da and summed together to produce the MRM<sup>3</sup> signal shown (Figure 2, bottom). Integration of the resulting peak provides the quantitative data.

#### Increased selectivity improves LLOQs

The MRM<sup>3</sup> workflow provides further specificity compared to MRM alone due to the additional level of selectivity obtained by monitoring secondary product ions. Three MRM transitions for the peptide DTINFLSK are shown at 4.8 fmol on column in Figure 3, top. Higher flow rates provided by the 200 µm cHiPLC column yield good peak shape; however, 2 of the 3 transitions showed significant interferences. The MRM<sup>3</sup> data shows much better specificity (Figure 3, bottom). A similar observation was made for the SLGPVGFMK peptide, where two of the three monitored MRM transitions showed some interference, but the MRM<sup>3</sup> data was very clean (Figure 5).



**Figure 5. Comparing MRM and MRM<sup>3</sup> specificity.** MRM<sup>3</sup> workflow provides high specificity by quantifying secondary product ions generated from a peptide of interest. Two of three MRM transitions detected for the SLGPVGFMK peptide of CYP450 3A5 (top) show significant interferences, where MRM<sup>3</sup> detection of secondary product ions from the peptide (bottom) provides a more selective detection.



Figure 4. Standard concentration curve for peptide DTINFLSK using MRM<sup>3</sup> Workflow. A linear concentration curve was obtained for the concentration range interrogated (top). A coefficient of variance of 2.7% and an accuracy of 116% was obtained at the LLOQ of 1.2 fmol on column, with the MRM<sup>3</sup> signal at the LLOQ shown in the bottom pane.

Concentrations curves for two peptides to the CYP 3A5 protein were generated in digested liver microsomes using heavy isotope labeled peptide standards. Both MRM and MRM<sup>3</sup> assays were performed, and lower limits of quantitation (LLOQ) determined by processing in MultiQuant Software. For both peptides, the MRM<sup>3</sup> assay provided lower limits of quantitation than the MRM assay. Quantitation limits of 1.2 fmol were obtained for MRM<sup>3</sup>, and actual signal at this level is shown in Figure 4 and 6, bottom. Good linearity was obtained across the concentration range interrogated – from LLOQ of 1.2 fmol to 805fmol on column in 1 µg of digested protein (Figure 4 and 6, top).



#### Conclusions

The quadrupole selectivity and linear ion trap sensitivity of the QTRAP 4500 System combine to produce a sensitive, flexible system for targeted peptide quantitation. MRM transitions designed for tryptic peptides to a protein are the standard method for quantitation of proteins by mass spectrometry. While MRM transitions can be very sensitive and selective, sometimes added selectivity is required due to the complexity of the matrices and the need to monitor unique low abundance peptides.

- The speed and sensitivity of the linear ion trap on the QTRAP 4500 System make MRM<sup>3</sup> analysis a robust quantitative strategy for peptides in complex matrices when significant background / interferences are present.
- The increased selectivity of MRM<sup>3</sup> allowed for the elimination of chromatographic interference, resulting in superior analytical performance compared to traditional MRM.



Figure 6. Standard concentration curve for peptide SLGPVGFMK using MRM<sup>3</sup> Workflow. A linear concentration curve was obtained for the concentration range interrogated (top). A coefficient of variance of 8.9% and an accuracy of 84% was obtained at the LLOQ of 1.2 fmol on column, with the MRM<sup>3</sup> signal at the LLOQ shown in the bottom pane.

#### References

1. MRM<sup>3</sup> quantitation for highest specificity in complex matrices. SCIEX technical note RUO-MKT-02-2739-A.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.

© 2017 DH Tech. Dev. Pte. Ltd. RUO-MKT-02-4845-A. AB SCIEX™ is being used under license.



Headquarters 500 Old Connecticut Path | Framingham, MA 01701 USA Phone 508-383-7700 sciex.com International Sales For our office locations please call the division headquarters or refer to our website at sciex.com/offices